Premium
Divascan (r) in Migraine Prophylaxis. Open Trial with Three Different Doses
Author(s) -
Osterman P.O.
Publication year - 1978
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.1978.hed1804225.x
Subject(s) - migraine , medicine , prophylactic treatment , anesthesia , migraine disorders , surgery
SYNOPSIS In an open trial 26 patients with severe migraine were treated with 3 different doses of Divascan (1‐isopropyl‐noradrenochrome‐5‐monosemicarbazone) ‐ 15, 30 and 40 mg a day. During treatment with Divascan there was a significant reduction in the number of migraine attacks and in the headache index compared with a preceding control period. The prophylactic effect of 30 and 40 mg Divascan a day seemed better than that of 15 mg a day. The headache frequency was significantly lower with 40 mg a day than with 15 mg a day. A good or very good effect of the treatment was reported by 24 per cent of the patients on 15 mg a day, by 48 per cent on 30 mg a day and by 57 per cent on 40 mg a day. No serious side‐effects were noted. Divascan seems to be a promising drug in the prophylactic treatment of migraine but further studies are needed to establish what doses are optimal in migraine prophylaxis.